Share

Meet the new EORTC Board

The year 2024 signals the beginning of a new governing mandate. We are delighted to announce that during the General Assembly held on Friday, 28 June 2024, the new EORTC Board was appointed.

We warmly welcome four distinguished new members to our Board: Mrs Caroline Artis, the new Chair of the Audit & Finance Committee; Dr Roberto Salgado, who joins as a board member; Professor Martin van den Bent, the new Chair of the Protocol Review Committee; and Early Career Investigator, Dr Jens Lehmann.

Additionally, we are pleased to announce that Dr Etienne Brain and Dr Mieke Van Hemelrijck have been re-elected for a second term, and Dr Jean-Pierre Bizzari will now serve as Special Advisor. The rest of the board members have been renewed in their current roles.

The full new Board will convene for the first time in September. The current President, Professor W. van der Graaf, will remain in position until June 2026, as approved by the General Assembly, ensuring continuity during the recent changes in the EORTC’s governance structure.

Back to news list

Related News

  • EORTC presents new results in neuro-oncology at EANO

  • In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group

  • New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults

  • New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors

  • EORTC calls for a balanced and feasible European Health Data Space (EHDS)

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025